FDA has approved Libtayo (cemiplimab-rwlc) for the first-line treatment of patients with advanced non-small cell lung cancer (locally advanced who are not candidates for surgical resection or definitive chemoradiation or metastatic) whose tumors have high PD-L1 expression (Tumor Proportion Score [TPS] > 50%) as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations.
Last summer, Anirban Maitra, a pathologist specializing in pancreatic cancer, joined the NYU Langone Health Laura and Isaac Perlmutter Cancer Center to co-lead its Gastrointestinal Cancer Center.
